Long-Term Follow-up of Bendamustine/Rituximab - Rituximab/Cytarabine (BR/RC) Induction Therapy for Previously Untreated Transplant-Eligible Patients with Mantle Cell Lymphoma (MCL)
Christine E. Ryan(Dana-Farber Cancer Institute), Reid W. Merryman(Harvard University), Marcus P. Watkins(Washington University in St. Louis), Robert Redd(Harvard University), Oreofe O. Odejide(Dana-Farber Cancer Institute), Amanda F. Cashen(Washington University in St. Louis), Caron A. Jacobson(Dana-Farber Cancer Institute), Philippe Armand(Harvard University), Imran Nizamuddin(Northwestern University), Neha Mehta–Shah(The University of Texas MD Anderson Cancer Center), Matthew S. Davids(Dana-Farber Cancer Institute), Brad S. Kahl(UW Health University Hospital), Nancy L. Bartlett(Washington University in St. Louis), Eric D. Jacobsen(Dana-Farber Cancer Institute), Armin Ghobadi(Washington University in St. Louis), Ann S. LaCasce(Otsuka (Japan)), Jennifer L. Crombie(Dana-Farber Cancer Institute), Austin I. Kim(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Hari S. Raman(Dana-Farber Cancer Institute)
Cited by 0
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k